We estimate that the net proceeds from this offering of securities, after deducting estimated offering expenses, will be approximately $9.5 million (without giving effect to any exercise of the Warrants). We intend to use the net proceeds from this offering and the proceeds from any exercise of the Warrants to fund clinical trials for our product candidates and for working capital and general corporate purposes.
Our management will have broad discretion in the application of these proceeds. We may, subsequent to this offering, pursue strategic opportunities that may arise, such as potential acquisition opportunities, although we have no current plans, commitments or agreements to do so as of the date of this prospectus supplement. The amounts and timing of our actual expenditures will depend on numerous factors, including our product development and commercialization efforts, our sales and marketing activities, the amount of cash used by our operations and our assessment of the ability to add long-term stockholder value through potential strategic opportunities. Investors will be relying on the judgment of our management regarding the application of these net proceeds.